相关实验视频
Updated: Jul 10, 2025

08:02
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
Published on: January 22, 2020
5.5K
在炎症性肠病中提供益生菌的单细胞修饰策略:一篇综述
Mengzhen Han1, Wenzhi Lei1, Jingjing Liang1
1College of Food Science and Engineering, Northwest A&F University, 712100 Yangling, Shaanxi, China.
Carbohydrate polymers
|November 20, 2023
概括
口服益生菌在治疗肠道疾病方面表现有前途,但生存是一个挑战. 单细胞修饰和封装增强了益生菌的传递和在炎症性肠病 (IBD) 的疗效.
科学领域:
- 胃肠道学和微生物学
- 生物技术和药物供应 生物技术和药物供应
背景情况:
- 口服益生菌疗法是治疗肠道屏障功能障碍,炎症性肠病 (IBD) 和结肠直肠癌的方便方法.
- 口服益生菌在胃肠道中的生存时间有限,阻碍了它们的治疗效果.
- 封装和益生菌功能化是改善益生菌生存,肠道殖民和宿主相互作用的策略.
研究的目的:
- 系统地审查在IBD治疗中益生菌的单细胞修饰策略的进展.
- 讨论这些新型益生菌修饰技术的局限性和未来前景.
主要方法:
- 对益生菌输送系统新兴单细胞修饰策略的审查.
- 对封装技术和功能多糖应用的分析.
- 在炎症性肠病的背景下讨论益生菌的性能.
主要成果:
- 单细胞修饰策略提供了增强的保护和有针对性的益生菌输送.
- 封装改善了在恶劣的胃肠道条件下益生菌的生存,并促进了肠道粘附.
- 使用益生菌的功能化可以提供额外的治疗益处.
结论:
- 单细胞修饰是开发IBD先进益生菌疗法的一个有希望的前沿.
- 对优化这些策略的进一步研究可以带来改进的输送系统,对结肠炎有更高的治疗疗效.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
132
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
132
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
337
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
337
Inflammatory Bowel Disease V: Surgical Management
148
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
148
Drugs for Treatment of Ulcerative Colitis in IBD
145
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
145
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
121
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
121

